From One Child to Many: Julia Vitarello's Quest to Scale Personalized Genetic Medicines

Julia Vitarello, the mother who fought for a custom-made drug to treat her daughter Mila's rare genetic condition, is now embarking on a new venture to produce such individualized therapies on a larger scale. Her previous company, EveryONE Medicines, recently shut down after encountering hurdles with regulatory and investor expectations. Below, we explore the story behind this pioneering effort and the challenges of making bespoke medicine widely accessible.

Who is Julia Vitarello and why is her story significant?

Julia Vitarello is the mother of Mila, a child with a severe neurological disorder caused by a unique mutation in the MEF2C gene. Eight years ago, Vitarello rallied scientists to create a personalized antisense oligonucleotide drug, nicknamed “milasen,” specifically designed to target Mila’s mutation. This marked one of the first successful instances of “n-of-1” therapy—a treatment tailored for a single patient. Her relentless advocacy not only saved Mila's life but also sparked a movement toward individualized genomic medicine. Now, Vitarello is launching a new biotechnology company to overcome the barriers that prevented her first venture from scaling. Her journey highlights both the promise and the systemic obstacles in delivering precision therapies to patients with ultra-rare diseases.

What was the bespoke medicine Mila received, and how did it work?

Mila’s drug, milasen, is an antisense oligonucleotide (ASO)—a short strand of synthetic DNA designed to correct the splicing error caused by her specific MEF2C mutation. In Mila’s case, the mutation led to the production of a faulty protein, causing severe seizures and developmental delays. Working with researchers at Boston Children’s Hospital and the Broad Institute, Vitarello helped engineer a drug that would bind to the mutated RNA and restore normal protein production. Remarkably, milasen was developed, tested in animals, and administered to Mila in under a year—a stunning turnaround for a drug normally requiring decades. The treatment significantly reduced her seizures and improved her quality of life, proving that truly personalized therapies could be both feasible and effective, even for a single patient.

Why did EveryONE Medicines, Vitarello’s first company, fail?

EveryONE Medicines, launched to produce ASO therapies for many patients with rare mutations, ceased operations primarily because of investor uncertainty. The company relied on the FDA releasing clear guidance for the development of customized therapies. While the agency did issue supportive statements, Vitarello said the guidance “did not go far enough” to create a predictable regulatory pathway that could reassure investors. Without a clear blueprint for approval, venture capitalists hesitated to fund a model where each therapy is unique and potentially non-replicable for large populations. Additionally, the high per-patient cost and the logistical complexity of manufacturing multiple distinct ASOs proved unsustainable under the current infrastructure.

What is the new company Vitarello is starting, and how is it different?

Vitarello’s next venture aims to tackle the scale problem that derailed EveryONE Medicines. While details remain limited, she intends to build a platform that can design, test, and manufacture individualized ASOs more efficiently and cost-effectively. The new biotech will likely leverage advances in artificial intelligence, automated oligonucleotide synthesis, and streamlined clinical validation—essentially a “factory” that can produce bespoke therapies in a repeatable way. Vitarello and her collaborators are currently seeking new funders who are willing to think differently about risk and reward in the ultra-rare space. The hope is to move from one-off “miracle” treatments to a sustainable model that can serve thousands of patients with unique mutations.

What role did the FDA play in shaping these efforts?

The U.S. Food and Drug Administration (FDA) has long recognized the potential of personalized medicine but struggles to adapt its traditional approval framework to “n-of-1” therapies. In recent years, the agency issued non-binding recommendations and pilot programs encouraging the development of customized ASOs. However, investors and companies like EveryONE Medicines found these measures insufficient to mitigate regulatory risk. Vitarello’s experience shows that without a clear, mandatory pathway for approval—perhaps involving provisional reimbursement or accelerated review—biotech firms face an uphill battle securing capital. The FDA’s next moves could determine whether personalized therapies become a standard option or remain rare exceptions.

What are the main challenges in scaling bespoke genetic medicines?

Scaling individualized therapies involves multiple hurdles:

• Regulatory clarity: No standard approval process exists for treatments targeting one or a few patients.
• High costs: Designing, testing, and manufacturing a unique drug for a single person is expensive, often exceeding $1 million per therapy.
• Manufacturing complexity: Each ASO requires separate synthesis quality control, creating bottlenecks.
• Patient identification: Finding the right candidates with specific mutations requires extensive genetic screening.
• Investor appetite: Venture capital typically prefers blockbuster drugs, not tiny markets.

Vitarello’s new company aims to address these issues by adopting modular technologies and collaborative networks. Success could pave the way for a new industry where “made for you” medicine becomes financially viable.

What are the next steps for Vitarello and her team?

Currently, Vitarello and her collaborators are actively searching for new funders—a mix of philanthropic, government, and venture sources—willing to support a high-risk, high-impact mission. They plan to build a team of experts in oligonucleotide chemistry, software engineering, and regulatory science. The initial focus will be on creating a scalable pipeline for a few dozen patients per year, aiming to prove that the model can work without losing money or quality. If they succeed, it could unlock a new paradigm in medicine: no patient left behind simply because their disease is too rare for a commercial drug.